Skip to main content

QURE

Stock

QURE

Stock
Health Care
Biotechnology

Performance overview

QURE Price
Price Chart

Forward-looking statistics

Beta
2.02
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees534
Market cap$258.8M

Fundamentals

Enterprise value$867.0M
Revenue$20.2M
Revenue per employee
Profit margin32.42%
Debt to equity1522.46

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.38
Dividend per share
Revenue per share$0.41
Avg trading volume (30 day)$16M
Avg trading volume (10 day)$12M
Put-call ratio

Macro factor sensitivity

Growth-5.5
Credit+11.4
Liquidity+3.6
Inflation-9.7
Commodities-2.9
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio-4.61
Price to sales38.27
P/E Ratio-4.61
Enterprise Value to Revenue42.92
Price to book22.92

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

Zacks Investment Research (May 21, 2025)
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday

Benzinga (April 17, 2025)
Final Trade: DVN, QURE, GOOGL, DFH

The final trades of the day with the Fast Money traders.

CNBC Television (December 30, 2024)
What Led To A 150% Rise In UniQure Stock In A Week?

uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease.

Forbes (July 12, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free